Latest & greatest articles for furosemide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on furosemide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on furosemide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for furosemide

1. Furosemide alone versus furosemide with albumin for the treatment of nephrotic edema in adults and children

Furosemide alone versus furosemide with albumin for the treatment of nephrotic edema in adults and children Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

2. Drugs - Furosemide (Frusemide, Lasix)

Drugs - Furosemide (Frusemide, Lasix) Furosemide (Frusemide, Lasix) FRM Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Ampoules containing furosemide 50 milligrams/5ml. OR Ampoules containing furosemide 40 milligrams/2ml. OR Pre-?lled syringe containing furosemide 80 milligrams. ACTIONS Furosemide is a potent diuretic with a rapid onset (within 30 minutes) and short duration. DOSAGE AND ADMINISTRATION Route: IV ADDITIONAL INFORMATION Nitrates are the first line treatment for acute pulmonary (...) oedema. Use furosemide secondary to nitrates in the treatment of acute pulmonary oedema where transfer times to hospital are prolonged. CAUTIONS Hypokalaemia (low potassium) could induce arrhythmias. Pregnancy. INDICATIONS Pulmonary oedema secondary to Left Ventricular failure (LVF). CONTRA-INDICATIONS Pre-comatose state secondary to liver cirrhosis, severe renal failure with anuria. Children <16 years. SIDE EFFECTS Hypotension. Gastro-intestinal disturbances. Administer SLOWL Y over 2 minutes. AGE

2007 Joint Royal Colleges Ambulance Liaison Committee

3. Peritoneal Dialysis vs Furosemide for Prevention of Fluid Overload in Infants After Cardiac Surgery: A Randomized Clinical Trial

Peritoneal Dialysis vs Furosemide for Prevention of Fluid Overload in Infants After Cardiac Surgery: A Randomized Clinical Trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2017 PedsCCM Evidence-Based Journal Club

4. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure. (PubMed)

Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure. Diuretics are the primary treatment for the management of chronic heart failure (HF) symptoms and for the improvement of acute HF symptoms. The rate of delivery to the site of action has been suggested to affect diuretic pharmacodynamics. The main objective of this clinical trial (...) was to explore whether a prolonged release tablet formulation of torasemide (torasemide-PR) was more natriuretically efficient in patients with chronic HF compared to immediate-release furosemide (furosemide-IR) after a single-dose administration. Moreover, the pharmacokinetics of torasemide-PR, furosemide-IR, and torasemide-IR were assessed in chronic HF patients as well as urine pharmacodynamics.Randomized, open-label, blinded-endpoint, crossover, and single-dose Phase I clinical trial with three

Full Text available with Trip Pro

2015 Drug design, development and therapy

5. Comparative effects of furosemide and other diuretics in treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials

Comparative effects of furosemide and other diuretics in treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

6. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. (PubMed)

Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. Loop diuretics are first-line medications for congestive heart failure (CHF); however, they are associated with serious adverse effects, including decreased renal function, and sympathetic nervous and renin-angiotensin system activation. We tested whether tolvaptan, a vasopressin V2-receptor antagonist, could reduce unfavourable furosemide-induced effects during CHF (...) treatment.Sixty patients emergently hospitalized owing to CHF-induced dyspnea were randomly assigned to receive either 40 mg intravenous furosemide daily or 7.5 mg oral tolvaptan for 5 days after admission. Both groups also received intravenous carperitide and canrenoate potassium. As results, baseline patient characteristics were similar between the furosemide (n = 30) and the tolvaptan (n = 30) groups, with no significant difference in 5 day urine volume or fluid balance. Brain natriuretic peptide and body

Full Text available with Trip Pro

2016 ESC heart failure

7. Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial

Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial (FADE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02055872 Recruitment Status : Completed First Posted : February 5, 2014 Last Update Posted : October 10, 2016 Sponsor: Hamilton Health Sciences Corporation

2014 Clinical Trials

8. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study. (PubMed)

Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study. Tolvaptan increases free water clearance (aquaresis) and thereby improves hyponatremia. Although hyponatremia on admission is common in patients with congestive heart failure (CHF), little is known regarding the response to tolvaptan in those who also have chronic kidney disease (CKD) with or without hyponatremia. The aim (...) of this subanalysis was to investigate the differences in treatment response between normo- and hyponatremia patients with CHF and CKD stages G3b-5.The Kanagawa Aquaresis Investigators Trial of Tolvaptan on HF Patients with Renal Impairment (K-STAR) was a multicenter, open-label, randomized, controlled prospective clinical trial that included 81 Japanese patients with CHF and residual signs of congestion despite oral furosemide treatment (≥40 mg/day). All patients were randomly assigned to 7-day treatment

2017 American journal of nephrology

9. Continuous infusion versus intermittent or bolus injection of furosemide in acute heart failure: a systematic review and meta-analysis

Continuous infusion versus intermittent or bolus injection of furosemide in acute heart failure: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

10. High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis. (PubMed)

High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis. We aimed to evaluate and compare the efficacy and safety of high-dose furosemide+salt orally by comparing HSS+ furosemide (i.v.) and repeated paracentesis in patients with RA.This was a prospective study of 78 cirrhotic patients with RA, randomized into three groups: Group A (n= 25) i.v. furosemide (200-300 mg bid) and 3% hypotonic saline solution (HSS) (once or twice a day); Group B (n= 26 (...) ) oral furosemide tablets (360-520 mg bid) and salt (2.5 g bid); and, Group C (n= 27) repeated large-volume-paracentesis (RLVP) with albumin infusion. Patients without hyperkalemia were administrated 100 mg of spironolactone/day. During the follow-up; INR, creatinine, and total bilirubin levels were measured to determine the change in MELD (model of end stage liver disease) score.Hepatic encephalopathy (HE), severe episodes of spontaneous bacterial peritonitis (SBP) and pleural effusions (PE

2016 Clinical and Investigative Medicine. Medecine Clinique et Experimentale

11. Furosemide

Furosemide Top results for furosemide - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for furosemide The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

12. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. (PubMed)

Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. This study investigated the effect of furosemide-forced diuresis and intravenous saline infusion matched with urine output, using a novel dedicated device designed for contrast-induced nephropathy (CIN) prevention.CIN is a frequent cause of acute kidney injury associated with increased (...) morbidity and mortality.A total of 170 consecutive patients with chronic kidney disease (CKD) undergoing coronary procedures were randomized to either furosemide with matched hydration (FMH group, n = 87) or to standard intravenous isotonic saline hydration (control group; n = 83). The FMH group received an initial 250-ml intravenous bolus of normal saline over 30 min followed by an intravenous bolus (0.5 mg/kg) of furosemide. Hydration infusion rate was automatically adjusted to precisely replace

Full Text available with Trip Pro

2012 JACC. Cardiovascular interventions

13. The Adjunctive Effect of Nebulized Furosemide in Acute Treatment of Patients with Chronic Obstructive Pulmonary Disease Exacerbation: A Randomized Controlled Clinical Trial. (PubMed)

The Adjunctive Effect of Nebulized Furosemide in Acute Treatment of Patients with Chronic Obstructive Pulmonary Disease Exacerbation: A Randomized Controlled Clinical Trial. To examine the effect of nebulized furosemide as an adjunct to the conventional treatment of patients with COPD exacerbation in an emergency department.In this randomized double-blinded clinical trial, patients with COPD exacerbation were randomized to receive 40 mg nebulized furosemide or placebo as an adjunct (...) to the conventional treatments. We recorded changes in dyspnea severity (measured with a visual analog scale), FEV1, arterial blood gas measurements, blood pressure, heart rate, and breathing frequency at baseline and 1 hour after treatment.We randomized 100 patients, whose mean age was 73.1 ± 8.7 y. The measured variables all improved significantly in both groups. FEV1, dyspnea, pH, mean blood pressure, and heart rate improved significantly more in the furosemide group.Nebulized furosemide benefits patients

Full Text available with Trip Pro

2013 Respiratory care

14. Why do we still use furosemide as our first line loop diuretic?

Why do we still use furosemide as our first line loop diuretic? db's Medical Rants » Blog Archive » Why do we still use furosemide as our first line loop diuretic? Internal medicine, American health care, and especially medical education 2 Posted by rcentor | Posted on 26-12-2016 Category : We currently have 3 loop diuretic options – furosemide (Lasix), bumetanide (Bumex) and torsamide (Demadex). They are all currently generic and available for 50 cents or less per pill. In the 70s, during my (...) residency I believe furosemide was already generic. The remaining two loop diuretics became available after my residency and thus had higher prices for several years. Here is the problem. Furosemide is inconsistently absorbed across people and averages only 50% but for some people absorption is even less. Bumetanide and torsamide get absorbed consistently and close to 95%. Several times this month we had patients admitted for increased edema. They all responded well to IV furosemide, but when we gave

2016 db's Medical Rants blog

15. Bolus Injection Versus Infusion of Furosemide in Kidney Transplantation: A Randomized Clinical Trial. (PubMed)

Bolus Injection Versus Infusion of Furosemide in Kidney Transplantation: A Randomized Clinical Trial. Furosemide is commonly administered to increase the urinary output in patients with transplanted kidneys. This study compared the two administration routes of furosemide (bolus versus infusion) in kidney transplanted patients.Fifty patients who had undergone kidney transplantation in 2015 in a hospital in Tabriz, Iran, were included in this clinical trial. They were divided into two groups (...) each three hours for 24 hours, and eventually two and three days thereafter. Finally, all data were statistically analyzed.Around 72% of the patients were men (mean age of 37.15 ± 14.67 years). Urine output was higher in bolus group but it was not statistically significant. Diuresis duration was measured after arterial declamping and its averages were 5.41 ± 3.7 minutes and 9.36 ± 7.65 minutes in bolus and infusion groups, respectively (P = .040). Furosemide bolus injection

2017 Urology journal

16. Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration

Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration (FUROPHARM-HF) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02350725 Recruitment Status : Completed First Posted : January 30, 2015 Last Update Posted : June 27, 2018 Sponsor

2014 Clinical Trials

17. #NephMadness Furosemide Stress Test Haiku Deck #CCRegion

#NephMadness Furosemide Stress Test Haiku Deck #CCRegion Renal Fellow Network: #NephMadness Furosemide Stress Test Haiku Deck #CCRegion | | | | | Saturday, March 7, 2015 #NephMadness Furosemide Stress Test Haiku Deck #CCRegion - Created with Haiku Deck, presentation software that inspires Post by Hector Madariaga. Go to the AJKD blog NephMadness region to read more. Posted by Matt Sparks at No comments: Subscribe to: Interested in Contributing to the Renal Fellow Network? Email Matt or Gearoid

2015 Renal Fellow Network

18. Furosemide (Frusemide, Lasix)

Furosemide (Frusemide, Lasix) Furosemide (Frusemide, Lasix) FRM Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Ampoules containing furosemide 50 milligrams/5ml. OR Ampoules containing furosemide 40 milligrams/2ml. OR Pre-?lled syringe containing furosemide 80 milligrams. ACTIONS Furosemide is a potent diuretic with a rapid onset (within 30 minutes) and short duration. DOSAGE AND ADMINISTRATION Route: IV ADDITIONAL INFORMATION Nitrates are the first line treatment for acute pulmonary oedema (...) . Use furosemide secondary to nitrates in the treatment of acute pulmonary oedema where transfer times to hospital are prolonged. CAUTIONS Hypokalaemia (low potassium) could induce arrhythmias. Pregnancy. INDICATIONS Pulmonary oedema secondary to Left Ventricular failure (LVF). CONTRA-INDICATIONS Pre-comatose state secondary to liver cirrhosis, severe renal failure with anuria. Children <16 years. SIDE EFFECTS Hypotension. Gastro-intestinal disturbances. Administer SLOWL Y over 2 minutes. AGE DOSE

2006 Joint Royal Colleges Ambulance Liaison Committee

19. Furosemide in postpartum management of severe preeclampsia: A randomized controlled trial. (PubMed)

Furosemide in postpartum management of severe preeclampsia: A randomized controlled trial. Hypertension in the postpartum period is a common phenomenon and is often a cause for concern. Following delivery, fluid that has been sequestered in the extravascular space is mobilized, producing a large auto-infusion of fluid from the extravascular to the intravascular compartment. As a result of this fluid mobilization process, there is an increase in central venous pressure and pulmonary capillary (...) wedge pressure, which might favor the development of pulmonary edema. Thus, diuretics logically might be a better choice as antihypertensive medication in such a scenario.A total of 108 antenatal women diagnosed with having severe preeclampsia, with two high blood pressure recordings of ≥150/100 mm of Hg in the postpartum period within the first 24 hours of delivery, were enrolled in the study. These patients were randomly divided into two groups (Group A: furosemide 20 mg OD + nifedipine & Group B

2016 Hypertension in pregnancy

20. Intermittent subcutaneous furosemide: parenteral diuretic rescue for hospice patients with congestive heart failure resistant to oral diuretic. (PubMed)

Intermittent subcutaneous furosemide: parenteral diuretic rescue for hospice patients with congestive heart failure resistant to oral diuretic. Patients with congestive heart failure (CHF) account for up to 12% of the hospice population and often experience significant symptoms related to volume overload. Diuretic therapy is the cornerstone of treatment but administration (PO) often becomes ineffective and (i.v., i.m.) routes cause discomfort or may not be feasible to ameliorate symptoms (...) . Subcutaneous dosing of furosemide has been explored as a potential alternative for management of CHF symptoms. We report 2 cases of CHF resistant to oral diuretic and examine the clinical utility of subcutaneous furosemide in an inpatient palliative care unit and a home hospice setting. Our case series supports the use of subcutaneous therapy as a potential alternative in palliative care and hospice patients.

2013 American Journal of Hospice and Palliative Medicine